Patent Application
20180306815
The invention relates to determining the concentration of an analyte(s) in a liquid test sample by immunochromatography techniques—such as an immunochromatographic strip. Immunochromatographic strip formats are frequently used for qualitative, semi-quantitative and quantitative assays that use visual and reflectance based detection schemes. This type of immunoassay involves the application of a liquid test sample suspected of containing an analyte to be detected to an application site of an immunochromatographic test strip. The strip includes a matrix material through which the liquid test medium and analyte suspended or dissolved therein can flow by capillarity from the application site to one or more capture sites where a detectable signal, or the absence of such, reveals the presence of the analyte. Respective capture sites may refer to specific locations of the test strip impregnated with reagents. Color changes, readable by an instrument and/or the human eye, of the capture sites is an indication of the presence and concentration of analyte in the test fluid. In particular embodiments, the matrix material is fabricated from an absorbent material which allows the analyte and labeled antibodies specific thereto to flow through it along with the fluid test sample and to form analyte/labeled antibody conjugates which can be captured in specific capture zones thereof, to provide a detectable response. Examples of test fluid include, but are not limited to, urine, blood, plasma, and serum.
In one aspect, the inventive concepts disclosed herein are directed to a lateral flow assay comprising: one or more chromatographic substrates, a sample application site, a first capture site, and a second capture site. A sample application site being located on each chromatographic substrate for application of a portion of a liquid sample. The first capture site disposed on a first chromatographic substrate and spaced apart from the application site such that when the liquid sample is applied to the sample application site the liquid sample moves through the first chromatographic substrate from the sample application site to the first capture site. The first capture site comprising an anti-hCG capture antibody with broad affinity for a group of multiple hCG variants, the presence of the group of hCG variants in the liquid sample being indicated at the first capture site by the presence of a first detectable signal caused by the presence of sandwich complexes at the first capture site. The second capture site disposed on the first chromatographic substrate or a second chromatographic substrate, the second capture site being spaced apart from the sample application site such that when the liquid sample is applied to the sample application site, the liquid sample moves through the first chromatographic substrate or a second chromatographic substrate from the sample application site to the second capture site, the second capture site comprising an anti-hCG capture antibody that is specific to a first variant of hCG, the presence of the first variant of hCG in the liquid sample being indicated at the second capture site by the presence of a second detectable signal caused by the presence of the sandwich complexes at the second capture site.
Additional aspects of the inventive concepts disclosed herein are directed to determining a ratio between the group of multiple hCG variants and the first variant of hCG in a liquid sample using the lateral flow assay strips described herein. For example, in another aspect of the inventive concepts disclosed herein, a method for determining the ratio includes: viewing the lateral flow assay after a liquid sample has been applied to the at least one sample application site such that the liquid sample has moved through the chromatographic substrate from the at least one sample application site towards the first capture site and the second capture site; obtaining a first concentration of a group of multiple hCG variants at the first capture site by evaluating the first detectable signal; obtaining a second concentration of a first hCG variant at the second capture site by evaluating the second detectable signal; and determining the ratio of the second concentration to the first concentration.
Additional aspects of the inventive concepts disclosed herein are directed to a system comprising an optical detector and a non-transitory computer-readable medium that stores instructions that cause the system having at least one processor to interpret the results of the lateral flow assay, after the liquid sample has been applied to the at least one sample application site such that the liquid sample has moved through the chromatographic substrate from the at least one sample application site towards the first capture site and the second capture site. The system: acquiring the concentration of a group of multiple hCG variants at the first capture site and the concentration of the hCGh variant at the second capture site by obtaining the respective first detectable signal and the second detectable signal, wherein the first detectable signal and the second detectable signal are obtained by measuring the reflectance of the first capture site and the second capture site, respectively, with the optical detector; and determining the ratio of the concentration of the hCGh variant in the liquid sample to the total concentration of all hCG variants in the liquid sample based on the obtained concentration of all hCG variants at the first capture site and the concentration of the hCGh variant at the second capture site.
Before explaining at least one embodiment of the inventive concepts disclosed herein in detail, it is to be understood that the inventive concepts are not limited in their application to the details of construction and the arrangement of the components or steps or methodologies set forth in the following description or illustrated in the drawings. The inventive concepts disclosed herein are capable of other embodiments or of being practiced or carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein is for the purpose of description and should not be regarded as limiting the inventive concepts disclosed and claimed herein in any way.
In the following detailed description of embodiments of the inventive concepts, numerous specific details are set forth in order to provide a more thorough understanding of the inventive concepts. However, it will be apparent to one of ordinary skill in the art that the inventive concepts within the instant disclosure may be practiced without these specific details. In other instances, well-known features have not been described in detail to avoid unnecessarily complicating the instant disclosure.
As used herein, the terms “comprises,” “comprising,” “includes,” “including,” “has,” “having” or any other variation thereof, are intended to cover a non-exclusive inclusion. For example, a composition, a process, method, article, or apparatus that comprises a list of elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherently present therein.
As used herein the terms “approximately,” “about,” “substantially” and variations thereof are intended to include not only the exact value qualified by the term, but to also include some slight deviations therefrom, such as deviations caused by measuring error, manufacturing tolerances, wear and tear on components or structures, settling or precipitation of cells or particles out of suspension or solution, chemical or biological degradation of solutions over time, stress exerted on structures, and combinations thereof, for example.
As used herein, the term “sample” and variations thereof is intended to include biological tissues, biological fluids, chemical fluids, chemical substances, suspensions, solutions, slurries, mixtures, agglomerations, tinctures, slides, powders, or other preparations of biological tissues or fluids, synthetic analogs to biological tissues or fluids, bacterial cells (prokaryotic or eukaryotic), viruses, single-celled organisms, lysed biological cells, fixed biological cells, fixed biological tissues, cell cultures, tissue cultures, genetically engineered cells and tissues, genetically engineered organisms, and combinations thereof, for example.
Unless expressly stated to the contrary, “or” refers to an inclusive or and not to an exclusive or. For example, a condition A or B is satisfied by anyone of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true (or present), and both A and B are true (or present). An inclusive or may be understood as being the equivalent to: at least one of condition A or B.
In addition, use of the “a” or “an” are employed to describe elements and components of the embodiments herein. This is done merely for convenience and to give a general sense of the inventive concepts. This description should be read to include one or at least one and the singular also includes the plural unless it is obvious that it is meant otherwise.
Finally, as used herein any reference to “one embodiment” or “an embodiment” means that a particular element, feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment. The appearances of the phrase “in one embodiment” in various places in the specification are not necessarily all referring to the same embodiment.
The invention relates to determining the concentration of an analyte(s) in a liquid test sample by immunochromatography techniques—such as an immunochromatographic strip. Immunochromatographic strip formats are frequently used for qualitative, semi-quantitative and quantitative assays that use visual and reflectance based detection schemes. This type of immunoassay involves the application of a liquid test sample suspected of containing an analyte to be detected to an application site of an immunochromatographic test strip. The strip includes a matrix material through which the liquid test medium and analyte suspended or dissolved therein can flow by capillarity from the application site to one or more capture sites where a detectable signal, or the absence of such, reveals the presence of the analyte. Respective capture sites may refer to specific locations of the test strip impregnated with reagents. Color changes, readable by an instrument and/or the human eye, of the capture sites is an indication of the presence and concentration of analyte in the test fluid. In particular embodiments, the matrix material is fabricated from an absorbent material which allows the analyte and labeled antibodies specific thereto to flow through it along with the fluid test sample and to form analyte/labeled antibody conjugates which can be captured in specific capture zones thereof, to provide a detectable response. Examples of test fluid include, but are not limited to, urine, blood, plasma, and serum.
An illustrative analyte of interest is human chorionic gonadotropin (hCG) and the variants thereof. Detection of hCG hormone in liquid test samples is a leading diagnostic test for pregnancy. Physiologically, hCG molecules exist within the human body in different metabolic states referred to as ‘hCG variants.’ Illustrative diagnostic tests may aim to detect a group of multiple hCG variants in a liquid sample in order to facilitate the determination of the total concentration of the hCG variants—this concentration may be referred to as ‘total hCG’ (hCGt). While certain illustrative diagnostic tests may, in fact, test for all hCG variants it should be understood that other illustrative diagnostic tests may only test for a subset of hCG variants. This subset of hCG variants can be selected in order to approximate the actual hCGt concentration in the liquid sample without actually testing for all hCG variants.
Each variant of hCG has a specific physiological function(s) whose expression varies with, for example, the stage of a pregnancy or the developing of a malignant formation. For example, illustrative variant hyperglycosylated hCG (hCGh) can be an important indicator in evaluating early pregnancy development (i.e., implantation), early pregnancy loss (EPL), and malignancies of the reproductive system. The uses of a hCGh specific antibody (such as monoclonal antibody B-152) allows for the discrete evaluation of the hCGh expression patterns from within the larger pool of total hCG—thus enabling the concentration of hCGh within a liquid sample to be determined.
Once the respective concentrations of hCGt and hCGh are determined, a ratio of hCGh to hCGt can be computed. This hCGh/hCGt ratio can be used, for example, to predict the outcome of pregnancies as well as the success of in vitro fertilization procedures.
Turning now to
Assay strip 100A is comprised of one or more chromatographic substrates 2A. Chromatographic substrates 2A, 2B may include any matrix material through which the liquid test medium and analyte suspended or dissolved therein can flow by capillarity. Chromatographic substrates 2A, 2B comprise a sample application site 4 for application of a portion of the liquid sample. Sample application site can be comprised of, for example, one or more of: a region on a respective chromatographic substrate 2A, 2B, a sample pad, or conjugate pad. Illustrative sample pads may be for receiving a sample application, sample treatment, and sample filtration. Illustrative conjugate pads may contain colloidal gold particles or colored latex particles (e.g., a label) coated with anti-beta hCG monoclonal antibody which mix with the sample liquid upon application of the sample liquid to the sample application site 4. The sample application site 4 should be located a distance from each of the capture sites such that the sample liquid flows from the sample application site 4 towards each capture site(s). For example, the sample application site 4 of the assay strip 100A in
Lateral flow assay strip 100A further contains a first capture site 6 disposed on the first surface of a first chromatographic substrate 2A. The first capture site 6 is spaced apart from the application site 4 such that when the liquid sample is applied to the sample application site 4, the liquid sample moves through the first chromatographic substrate 2A from the sample application site 4 to the first capture site 6. The first capture site 6 comprises an anti-hCG capture antibody with broad affinity for the group of multiple hCG variants (as described above) which are collectively referred to as hCGt. For example, first capture site 6 may be a region of anti-hCG antibody, such as a goat polyclonal anti-hCG antibody. Once sample liquid, moving through the substrate 2A, reaches the first capture site 6, the presence of the hCG variants in the liquid sample is indicated by the presence of a first detectable signal 14 caused by the formation of an antibody-hCG-antibody-colloidal gold particle (e.g., a ‘label’) complex at the first capture site 6. The first detectable signal 14 is a color change of the first capture site 6. The first detectable signal 14 can be visually measured by an individual or determined using an instrument which measures the amount of light reflected by the complex at the first capture site 6 (e.g., measures the detectable signal 14). The more intense the color of the first detectable signal 14, the higher the concentration of total hCG in the sample. It should be appreciated that while the first capture site 6 and the first detectable signal 14 are illustrated in the Figures as straight lines, they may take on a variety of other shapes and configurations without departing from the spirit of this disclosure.
Lateral flow assay strip 100A further contains a second capture site 8 that can be located on the first surface of the first chromatographic substrate 2A—along with the first capture site 6—or a second, separate chromatographic substrate 2B—as will be described below in connection with
The lateral flow assay strip 100A may also be provided with a control site 12 located on the first surface. Control site 12 may comprise of one or more anti-species antibodies—such as goat anti-mouse IgG, goat anti-donkey IgG, or donkey IgG label—impregnated into the substrate 2. The control site 12 may be located past the capture sites 6, 8 in the direction of sample liquid flow. In other words, one or both of capture sites 6, 8 are located in between the control site 12 and the sample application site 4. Appearance of control detectable signal 18 confirms that the correct procedures were used. Thus, it confirms that sample was added, it mixed with and solubilized the colored particle dried to the pad and the complex flowed through the membrane resulting in binding of the colored particle to at the control site 12. It should be understood that lateral flow assay strip 100A may further contain additional sites as well—such as a reference site (the absence of a signal at which indicates the test results are invalid).
In the example of
The illustrative embodiments of the lateral flow assays 100A through 100E depicted in
The ratio of the concentration of the hCGh variant in the liquid sample to the total concentration of all hCG variants (e.g., hCGt) in the liquid sample may then be determined based on the obtained concentration of hCGt variants at the first capture site and the obtained concentration of the hCGh variant at the second capture site. The manner in which the ratio of hCGh to hCGt can be computed varies on the configuration of the lateral flow assay 100. For example, where the lateral flow assay is configured so that liquid sample flowing from the sample application site 4 passes through either the first capture site 6 or the second capture site 8—but not both (as in lateral flow assays 100B through 100E)—the ratio can be computed by simply dividing the obtained concentration of hCGh by the obtained concentration of hCGt. The ratio can also be visually computed by visually comparing the intensity of the first detectable signal 14 against the intensity of the second detectable signal 16 with or without the aid of a reference source.
Alternatively, when the liquid sample, moving through the first chromatographic substrate, moves through the second capture site 8 and then first capture site 6—as is the case with the embodiment described in connection with
hCGh/hCGt ratio=(R1)/(R1+R2) (Equation 1).
In yet another illustrative example, the ratio can be determined by comparing the intensities of the first detectable signal 14 and the second detectable signal 16 of any one of lateral flow assays 100A-100E against a reference table. The reference table may index one or more hCGh/hCGt ratios—listed in individual cells—as a function of corresponding hCGh concentrations and hCGt concentrations—respectively listed in a first column and first row of the reference table. Using the reference chart, an individual can use hCGh concentrations and hCGt concentrations—determined using a reference source—to find the corresponding hCGh/hCGt ratio. Alternatively, an illustrative reference chart may index one or more hCGh/hCGt ratios—listed in individual cells of the reference chart—as a function of reference values for hCGh concentrations and hCGt concentrations (as described above) respectively depicted in a first column and first row of the reference table. This configuration may allow a user to determine an hCGh/hCGt ratio by matching the first detectable signal 14 and the second detectable signal 16 with reference color/intensity values in the first row/column of reference table.
While the illustrative embodiments of lateral assay strips 100 described above relate to hCGh and hCGt, the above described lateral flow assays can also be used to determine the ratio between hCGt and other variants. For example, lateral assay strips 100 can be used to compute the ratio of hCGt to hCG beta core fragment (‘hCGbcf’). Formed when urine is processed by the kidneys, too high of a concentration of hCGbcf in urine may invalidate a test result. This “high dose hook effect” often results in false negatives—putting patients at high risk of improper treatment. The embodiments of the lateral flow assays 100 above can be adapted to test for the hCGt to hCGbcf ratio by replacing the anti-hCG capture antibody of the above described second capture site 8 with an anti-hCG capture antibody—known to those skilled in the art—that is specific to the hCGbcf variant of hCG. Depending on the configuration of the lateral flow assay 100, the hCGt to hCGbcf ratio can be computed in the manner described above and below.
It should be further understood that, while the illustrative embodiments of lateral assay strips 100 described above relate to variants of hCG, the above described lateral flow assays can also be used to determine the ratio between any two analytes—or variants thereof—present in the liquid sample and is not limited to hCG and the variants thereof.
While the lateral flow assays 100A-100E shown and described above are strips, it should be appreciated by one of skill in the art that a lateral flow assay may also be incorporated into a cassette structure. An illustrative cassette may be a disposable, single-use cassette for doing a lateral flow immunoassay tests, for example, in the conventional manner. For example, the cassette may integrate the lateral flow assay into a housing which is comprised of a top piece, which defines a window, and a bottom piece. The cassette may have an opening or well in the top piece into which a fluid sample, such as urine, is placed so as to come into contact with the lateral flow assay. The housing may contain another window through which the first and second detectable signals 14, 16 can be viewed.
Embodiments of the lateral flow assay, including those lateral flow assays 100A-E as shown and described above, may be interpreted by a reflectance-based optical detector instrument 200. An illustrative example of such an instrument 200 is a reflectance spectroscope, or “reflectometer,” which is shown in
Instrument 200 may include an input and output device in the form of a touch screen 202. An output port 204 may be provided as a means for printing a report (e.g., test or diagnostic report) to an operator or user of machine 200. As will also be appreciated by those skilled in the art, other forms of input and output mechanisms may be used. For example, Instrument 200 may be configured to couple, by wired or wireless means, to an external computer, handheld computer, network, monitor, printer, audio/visual system or the like. A housing 206 houses the touch screen 202, as well as a variety of internal functional elements. An input port 208 is provided to facilitate insertion of one or more lateral flow assays 100 via a carriage (not shown).
Instrument 200 further comprises an optical sensor for the optical inspection of lateral flow assays 100, a non-transitory computer-readable storage medium on which computer-executable instructions are stored, and a processor. While not shown in
Once a portion of the liquid sample has been allowed to flow from the sample application site 4 to the capture sites 6, 8 of a lateral flow assay 100, the Instrument 200 can be used to analyze the first detectable signal 14 and the second detectable signal 16. For example, the optical sensor—in cooperation with the Processor and/or the computer-executable instructions—may measure the first and second detectable signals 14, 16 by measuring the characteristics of the light which is reflected (i.e., the reflectance) by the complexes at the respective first capture site 6 and the second capture site 8. The results of this measurement are then used by the processor to determine the corresponding hCGt and hCGh concentrations, respectively. The processor can identify the corresponding hCGt and hCGh concentrations by comparing the measured characteristics of the first and second detectable signals 14, 16 to reference data stored in the computer-readable storage medium. As one of skill in the art will appreciate, the reference data may comprise reference measurements that are correlated to known concentrations of hCGt and hCGh. By finding a reference measurement that corresponds to a measured characteristic, the processor can determine the concentrations of hCGt and hCGh in the liquid samples. The processor may then output the determined detectable signals 14, 16 to an output device (such as screen 202 or printer 204), an external computing platform, or a data storage device. The processor may also compute the hCGh/hCGt ratio, as described above, using the determined hCGt and hCGh concentrations and output the same. Alternatively, when the processor has outputted the determined detectable signals 14, 16 to an external computing device, that external device may use the received detectable signals 14, 16 to compute the hCGh/hCGt ratio, as described above.
Processor may have any suitable architecture, such as a general processor, central processing unit, digital signal processor, application specific integrated circuit, field programmable gate array, digital circuit, analog circuit, combinations thereof, or any other now known or later developed device for processing data. Likewise, processing strategies may include multiprocessing, multitasking, parallel processing, and the like. A program may be uploaded to, and executed by, the processor. The processor implements the program alone or includes multiple processors in a network or system for parallel or sequential processing.
The processor may perform the workflows, machine learning, model training, model application, and/or other processes described herein. For example, the processor or a different processor is operable to extract terms for use in modeling, learn a probabilistic model, and apply the trained probabilistic model. For applying the model, the model may have been trained by a different processor or the same processor. The processor outputs the state and/or associated information on the display, into a memory, over a network, to a printer, or in another media. The display is text, graphical, or other display.
The processor operates pursuant to instructions. The instructions and/or patient records for training a probabilistic model or for inferring a medical concept from a medical transcript are stored in a computer readable memory such as an external storage, ROM, and/or RAM. The instructions for implementing the processes, methods and/or techniques discussed herein are provided on computer-readable storage media or memories, such as a cache, buffer, RAM, removable media, hard drive or other computer readable storage media. Computer readable storage media include various types of volatile and nonvolatile storage media. The functions, acts or tasks illustrated in the figures or described herein are executed in response to one or more sets of instructions stored in or on computer readable storage media. The functions, acts or tasks are independent of the particular type of instructions set, storage media, processor or processing strategy and may be performed by software, hardware, integrated circuits, firmware, micro code and the like, operating alone or in combination. In one embodiment, the instructions are stored on a removable media device for reading by local or remote systems. In other embodiments, the instructions are stored in a remote location for transfer through a computer network or over telephone lines. In yet other embodiments, the instructions are stored within a given computer, CPU, GPU or system. Because some of the constituent system components and method acts depicted in the accompanying figures may be implemented in software, the actual connections between the system components (or the process steps) may differ depending upon the manner of programming.
Additionally, methods of using the lateral flow assays 100, as described above, may include the steps of providing or teaching an individual with some or all of the necessary information and/or materials described above. An illustrative method for determining a ratio of hCGh to hCGt in a liquid sample may comprise the following steps; teaching the step of viewing any of the lateral flow assays 100 the liquid sample has been applied to the at least one sample application site such that the liquid sample has moved through the chromatographic substrate 2A, 2B from the at least one sample application site 4 towards the first capture site 6 and the second capture site 8; teaching the step of obtaining the concentration of total hCG variants at the first capture site 6 by evaluating the first detectable signal 14; teaching the step of obtaining the concentration of the hCGh variant at the second capture site 8 by evaluating the second detectable signal 16; and teaching the step of determining the ratio of the concentration of the hCGh variant in the liquid sample to the total concentration of all hCG variants in the liquid sample based on the obtained concentration of all hCG variants at the first capture site 6 and the obtained concentration of the hCGh variant at the second capture site 8. Illustrative methods may further include: providing or teaching the use of a first reference value, the first reference value corresponding to a known concentration of all hCG variants in a first reference liquid sample; and providing or teaching the use of a second reference value, the second reference value corresponding to a known concentration of the hCGh variant in a second reference liquid sample. The step of obtaining the concentration of all hCG variants at the first capture site may also comprise teaching the step of comparing the first detectable signal against the first reference value. The step of obtaining the concentration of the hCGh variant at the second capture site may also comprise teaching the step of comparing the second detectable signal against the second reference value.
The foregoing description is provided for the purpose of explanation and is not to be construed as limiting individual lateral flow assays 100. Although the embodiments have been described herein with reference to particular structure, methods, and embodiments, the lateral flow assays 100 are not intended to be limited to the particulars disclosed herein. For instance, it should be appreciated that structure and methods described in association with one embodiment are equally applicable to all other embodiments described herein unless otherwise indicated. Those skilled in the relevant art, having the benefit of the teachings of this specification, may effect numerous modifications to individual lateral flow assays 100 as described herein, and changes may be made without departing from the spirit and scope of the of this disclosure, for instance as set forth by the appended claims.
The following is a numbered list of non-limiting, illustrative embodiments of the inventive concepts disclosed herein:
1) A lateral flow assay comprising:
one or more chromatographic substrates;
a sample application site on each chromatographic substrate for application of a portion of a liquid sample;
a first capture site disposed on a first chromatographic substrate, the first capture site being spaced apart from the application site such that when the liquid sample is applied to the sample application site the liquid sample moves through the first chromatographic substrate from the sample application site to the first capture site, the first capture site comprising an anti-human chorionic gonadotropin (‘hCG’) capture antibody with broad affinity for a group of multiple hCG variants, the presence of the group of hCG variants in the liquid sample being indicated at the first capture site by the presence of a first detectable signal caused by the presence of sandwich complexes at the first capture site; and a second capture site disposed on the first chromatographic substrate or a second chromatographic substrate, the second capture site being spaced apart from the sample application site such that when the liquid sample is applied to the sample application site, the liquid sample moves through the first chromatographic substrate or a second chromatographic substrate from the sample application site to the second capture site, the second capture site comprising an anti-hCG capture antibody that is specific to a first variant of hCG, the presence of the first variant of hCG in the liquid sample being indicated at the second capture site by the presence of a second detectable signal caused by the presence of the sandwich complexes at the second capture site.
2) The lateral flow assay of illustrative embodiment 1, wherein the first capture site and the second capture site are disposed on the first chromatographic substrate.
3) The lateral flow assay of any of illustrative embodiments 1 and 2, wherein first capture site and the second capture site are disposed on a first chromatographic substrate along a first liquid sample flow path, the first liquid flow path extending from a first sample application site toward both of the first and the second capture sites.
4) The lateral flow assay of any of illustrative embodiments 1 to 3, wherein liquid sample moving through the first chromatographic substrate reaches the second capture site before reaching the first capture site.
5) The lateral flow assay of any of illustrative embodiments 1 to 3, wherein liquid sample moving through the first chromatographic substrate reaches the first capture site and the second capture site at approximately the same time.
6) The lateral flow assay of any of illustrative embodiments 1 to 5, wherein the first capture site is disposed on a first surface of the first chromatographic substrate along a second liquid sample flow path extending from the sample application site to the first capture site, wherein the second capture site is disposed on the first surface of the first chromatographic substrate along a third liquid sample flow path, wherein the second liquid sample flow path does not extend through the second capture site, wherein the third liquid sample flow path does not extend through the first capture site.
7) The lateral flow assay of illustrative embodiment 6, wherein second and third flow paths are at an angle from one another.
8) The lateral flow assay of illustrative embodiment 6, wherein second and third flow paths are parallel to one another.
9) The lateral flow assay of any of illustrative embodiments 1 to 8, wherein the lateral flow assay comprises a single sample application pad.
10) The lateral flow assay of any one of illustrative embodiments 1 to 8, wherein the lateral flow assay contains a first substrate and a second substrate, the first substrate comprising the first capture site and the second substrate comprising the second capture site.
11) A method of determining a ratio comprising:
viewing the lateral flow assay of any of claims 1 to 10 after a liquid sample has been applied to the at least one sample application site such that the liquid sample has moved through the chromatographic substrate from the at least one sample application site towards the first capture site and the second capture site;
obtaining a first concentration of a group of multiple hCG variants at the first capture site by evaluating the first detectable signal;
obtaining a second concentration of a first hCG variant at the second capture site by evaluating the second detectable signal; and
determining the ratio of the second concentration to the first concentration.
12) The method of illustrative embodiment 11, wherein the step of obtaining the first concentration comprises comparing the first detectable signal against a first reference value, the first reference value corresponding to a known concentration of the group of multiple hCG variants in a first reference liquid sample in a corresponding lateral flow assay; and
wherein the step of obtaining the second comprises comparing the second detectable signal against a second reference value, the second reference value corresponding to a known concentration of the first hCG variant in a second reference liquid sample in the corresponding lateral flow assay.
13) The method of illustrative embodiment 12, wherein liquid sample moving through the first chromatographic substrate reaches the second capture site before reaching the first capture, and wherein determining the ratio of the second concentration of the first variant (R1) in the liquid sample to the first concentration of the group of hCG variants (R2) in the liquid sample comprises using the equation:
(R1)/(R1+R2) (Equation 1).
14) The method of illustrative embodiment 12, wherein determining the ratio comprises obtaining the ratio from a reference table, the reference table listing the determined ratio as a function of the first reference value and the second reference value.
15) A method of determining a ratio of comprising:
teaching the step of viewing the lateral flow assay of any of claims 1 to 9 after the liquid sample has been applied to the at least one sample application site such that the liquid sample has moved through the chromatographic substrate from the at least one sample application site towards the first capture site and the second capture site;
teaching the step of obtaining a first concentration of a group of multiple hCG variants at the first capture site by evaluating the first detectable signal;
teaching the step of obtaining a second concentration of a first hCG variant at the second capture site by evaluating the second detectable signal; and
teaching the step of determining the ratio of the second concentration to the first concentration.
16) The method of illustrative embodiment 15, further comprising:
providing or teaching the use of a first reference value, the first reference value corresponding to a known concentration of the group of multiple hCG variants in a first reference liquid sample; and
providing or teaching the use of a second reference value, the second reference value corresponding to a known concentration of the first hCG variant in a second reference liquid sample,
wherein the step of obtaining the first comprises comparing the first detectable signal against the first reference value; and
wherein the step of obtaining the second concentration comprises comparing the second detectable signal against the second reference value.
17) A system comprising an optical detector and a non-transitory computer-readable medium that stores instructions that cause the system having at least one processor to interpret the results of the lateral flow assay of any of claims 1 to 9, after the liquid sample has been applied to the at least one sample application site such that the liquid sample has moved through the chromatographic substrate from the at least one sample application site towards the first capture site and the second capture site, by:
acquiring the concentration of a group of multiple hCG variants at the first capture site and the concentration of a first variant at the second capture site by obtaining the respective first detectable signal and the second detectable signal, wherein the first detectable signal and the second detectable signal are obtained by measuring the reflectance of the first capture site and the second capture site, respectively, with the optical detector; and
determining the ratio of the concentration of the first hCG variant in the liquid sample to the concentration of the group of multiple hCG variants in the liquid sample based on the obtained concentration of the group of multiple hCG variants at the first capture site and the concentration of the first hCGh variant at the second capture site.
18) The device of illustrative embodiment 17, wherein the step of obtaining the concentration of the group of hCG variants at the first capture site comprises comparing the first detectable signal against a first reference value, the first reference value corresponding to a known concentration of the group of hCG variants in a first reference liquid sample; and wherein the step of obtaining the concentration of the first hCG variant at the second capture site comprises comparing the second detectable signal against a second reference value, the second reference value corresponding to a known concentration of the first hCG variant in a second reference liquid sample.
19) The system of illustrative embodiment 17, wherein liquid sample moving through the first chromatographic substrate reaches the second capture site before reaching the first capture site (e.g., the device of claim 4), and wherein determining the ratio of the concentration of the first variant (R1) in the liquid sample to the total concentration of the group of hCG variants (R2) in the liquid sample comprises using the equation:
(R1)/(R1+R2) (Equation 3).
20) The system or method of any of illustrative embodiments 1 to 20, wherein the first hCG variant is hyperglycosylated human chorionic gonadotropin.
21) The system or method of any of illustrative embodiments 1 to 20, wherein the first hCG variant is human chorionic gonadotropin beta core fragment.
22) The system or method of any of illustrative embodiments 1 to 21, wherein the group of hCG variants comprises all variants of hCG.
The subject application claims benefit under 35 USC § 119(e) of U.S. Provisional Application No. 62/081,138, filed Nov. 18, 2014. The entire contents of the above-referenced patent application are hereby expressly incorporated herein by reference.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US15/61078 | 11/17/2015 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 62081138 | Nov 2014 | US |
